If the FDA changes its guidelines regarding endpoints, the new guidance will govern FDA decision making at the approval/disapproval point -- i.e., at the end of its process. In this case, assuming an NDA, sometime in 2025. Not now, and not when the Anavex 2b/3 protocols were established years ago.
Market Data 
Markets 
